CN107167541A - The method for determining the DTPA Zn in rat plasma biological sample - Google Patents
The method for determining the DTPA Zn in rat plasma biological sample Download PDFInfo
- Publication number
- CN107167541A CN107167541A CN201710553621.6A CN201710553621A CN107167541A CN 107167541 A CN107167541 A CN 107167541A CN 201710553621 A CN201710553621 A CN 201710553621A CN 107167541 A CN107167541 A CN 107167541A
- Authority
- CN
- China
- Prior art keywords
- dtpa
- rat
- plasma
- biological sample
- auc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Abstract
The present invention relates to the method for determining the DTPA Zn in rat plasma biological sample.Specifically, the present invention relates to the method for determining the DTPA Zn in rat plasma biological sample, this method is determined the content of the DTPA Zn in the rat plasma biological sample through processing using liquid chromatography tandem mass spectrometry, comprised the following steps：(1) processing of biological sample, (2) Liquid Chromatography-Tandem Mass Spectrometry is determined, (3) data process＆analysis.The inventive method shows the excellent effect as described in description of the invention, such as with the excellent rate of recovery.
Description
Technical field
The invention belongs to biomedicine technical field, be related to a kind of reliable method to determine organism such as people, it is big
Mouse give biological sample after above-mentioned DTPA- metal-chelators such as blood, urine in above-mentioned metal-chelator content, to assess
The therapeutic effect of these metal-chelators or its behavior in vivo.
Especially, the present invention relates to a kind of method for determining the DTPA-Zn in rat plasma biological sample.
Background technology
The harm of lead contamination and lead poisoning to health has been received significant attention.Lead is human body non-essential element,
Absorption of human body is mainly entered by respiratory tract, alimentary canal, can be accumulated in vivo, it is toxic to each system of whole body and organ to make
With, main influence nerve, digestion, hematological system, lead contamination and lead poisoning are the public health problem [Hao for needing emphasis to solve
FT,Du XQ,Niu YM,et al.Progress in research of the lead intoxication[J].Chin J
Ind Med (Chinese industrial medical journal), 2008,21:200-202.1；Zhou QQ,Hu FF,Xia CY,et al.Study
progress on health hazards in occupational lead-exposed workers[J].Chin J Ind
Med (Chinese industrial medical journal), 2013,26:353-356].In terms for the treatment of, calcium disodium edetate is used as choice drug
For clinic [Zhou JY, Duan Z, Deng JX, et al.Clinical observation on chronic lead
poisoning treated with different dosages of CaNa-EDTA[J].Occup Health Emerg
Resue (occupational health and emergency management and rescue), 2002,20:159-160].Calcium disodium edetate treatment lead poisoning has good treatment
Effect, but while lead is complexed, also complexing discharge internal zinc, calcium, manganese, iron, copper etc., can cause internal essential trace element
, there is toxic side effect in dysequilibrium, and most important toxic side effect is renal damage caused by zinc missing.
Ca-DTPA (DTPA-Ca can be denoted as not only) also known as Ca DTPA salt and Zn-DTPA (but also can
It is denoted as DTPA-Zn) also known as diethylene-triamine pentaacetic acid trisodium zinc salt, the two belongs to complexones together, in August, 2004 by U.S.
State FDA ratifies to list simultaneously, is stained with for entering the work of radionuclide severe contamination place or stopping preceding and radionuclide
Treatment [Cada DJ, Levien T, Baker DE.Pentetate calcium trisodium (Ca-DTPA) and after dye
pentetate zinc trisodium(Zn-DTPA)[J].Hospital pharmacy,2005,40:65-71]。Zn-DTPA
With Ca-DTPA in vivo can optionally with radionuclide lanthanum (140La), cerium (144Ce), promethium (147Pm), americium (124Am),
The soluble complexes of the cation formation stability of plutonium (239Pu) etc., are excreted through kidney, so as to reduce in vivo quickly
The deposition of radioactive substance.Because Ca2+ with DTPA complexation constant is less than Zn2+ [Xue HL.The chelator
Treatment of common metal intoxication [J] .Chem Ind Occup Saf Health (work by chemical industry
Protection), 1989,10:22-26], DTPA is easier to the cation complex with nucleic in Ca-DTPA, therefore the effect of its decorporation is better than
Zn-DTPA.But toxicologic study is shown, Ca-DTPA easily causes endogenic zinc missing, so that the work of the enzyme relevant with zinc
Property influenceed by serious, including DNA and RNA polymerase, carboxypeptidase, carbonic anhydrase etc., liver kidney, intestinal mucosa can be caused
Adverse reaction [Shen BY, Ruan TM, the Wu DC.Effect of Zn-DTPA on the such as damage and hematopoietic repair
decorporation of ultra-Uranium,ultra-Plutonium and Lanthanide and its
Application [J] .Foreign Med Sci (Radit Med Nucl Med) [foreign medical science (Radiation Medicine nuclear medicine point
Volume)], 1988,12:70-74；Zhao XC,Wu DC.Toxicity of DTPA and its application on the
Decorporation of nuclide [J] .Foreign Med Sci (Radit Med) [foreign medical science (Radiation Medicines point
Volume)], 1980,4:211-215].Zn-DTPA security is higher, though the missing of the trace element such as manganese and magnesium can be also caused,
Zinc-deficiency will not be caused and serious toxic side effect is produced, 1/10~1/30 [the Zhang ZY, Xu that its toxicity is about Ca-DTPA
XW, Zhu Z.Pentetate zinc trisodium [J] .Chin Pharm J (Chinese Pharmaceutical Journal), 2007,42:557-
558]。
Existing document determines lead content using sampling Graphite Furnace Atomic Absorption spectrophotometer method, has investigated Zn-DTPA to chronic
Decorporation effect [Yang S, Chen L, Yin YY, the et al.Study of the effect of of mice with lead poisoning
pentetate zinc trisodium on excretion of lead in lead poisoned mice[J].Pharm
J Chin PLA (PLA's Acta Pharmaceutica Sinica), 2011,27:147-149], but sampling Graphite Furnace Atomic Absorption spectrophotometer method is surveyed
Determine that method is complicated, cost is high, sensitivity is low, be difficult to meet to determine for the amount in the biological sample such as blood, urine and require.
In addition, also document [Chen Li, etc. decorporation effects of the ICP-MS methods analysis Zn-DTPA to mice with lead poisoning, pharmacy
Journal (Acta Pharmaceutica Sinica) 2014,49 (11):1588-1592] report, using inductance coupled plasma
Constitution spectrum (ICP-MS) determines the concentration of lead in biological specimen, investigates decorporations of the nucleic decorporation medicine Zn-DTPA to mice with lead poisoning
Effect.Mouse disposable celiac injects acetic acid lead solution, and every dye lead 1mg sets up 4h abdominal cavities after acute lead poisoning model, dye lead
Inject Zn-DTPA, successive administration 5 days.Normal group, dye lead model group, Zn-DTPA and Ca-DTPA combination groups are set simultaneously.Often
It collects urine, in the dead some animals in the natural gift other places of the 2nd, 4 and 6 of experiment, takes whole blood, bilateral femur, brain, clears up after processing,
Lead content is determined with ICP-MS.It is believed that as a result showing that Zn-DTPA can dramatically increase the discharge of lead in urine, reduction blood, femur and brain
Lead content in tissue.
However, because DTPA-Ca and DTPA-Zn can be used not only for excluding internal heavy metal lead, can also exclude in vivo
The heavy metal such as lanthanum, cerium, promethium, americium, plutonium even can also be used to make a definite diagnosis as clinical practice medicine or it is doubtful by plutonium, americium, hard iron in vivo
The treatment of subject is polluted, and improves the clearance rate of these metallic elements.It is widely applied under environment, only investigates so
Lead distribution in vivo and content are obviously not enough to evaluate the internal behavior of this metal-chelators of DTPA.
Therefore, this area still expects have reliable method to give above-mentioned metal chelating to determine organism such as people, rat
The content of above-mentioned metal-chelator during biological sample is such as blood, urine after mixture, to assess the treatment of these metal-chelators
Effect or its behavior in vivo.
The content of the invention
It is an object of the invention to provide a kind of reliable method above-mentioned metal is given to determine organism such as people, rat
The content of above-mentioned metal-chelator during biological sample is such as blood, urine after chelating agent, to assess controlling for these metal-chelators
Therapeutic effect or its behavior in vivo.It has been had now surprisingly been found that, use liquid chromatography-tandem mass spectrometry (LC-MS/ of the present invention
MS) method, can effectively realize above-mentioned purpose.Particularly, the present invention is surveyed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
Determine the DTPA-Zn in rat plasma biological sample, show excellent Methodological characteristics.The present invention is consequently found that and be able to
Into.
Therefore, first aspect present invention is related to a kind of method for determining the DTPA-Zn in rat plasma biological sample, the party
Method determines the DTPA-Zn's in the rat plasma biological sample through processing using liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
Content, comprises the following steps：
(1) processing of biological sample：
(1a) takes the μ L of rat plasma 50 for containing or not contain DTPA-Zn, is placed in 1.5mL centrifuge tubes, plus inner mark solution
That is the 25 μ g/mL μ L of the EDTA-Zn aqueous solution 10 are not added with inner mark solution, the μ L of 0.1% ammoniacal liquor 50, the μ L of water 400, vortex mixing
3min, is all splined on solid phase extraction column；
Cleaned, finally eluted with the methanol 1mL containing 5% ammoniacal liquor with 1mL water, 1mL methanol successively after (1b) loading；
(1c) collects the eluent, drying, is redissolved with the μ L of 50% methanol 150 containing 0.05% ammoniacal liquor, draws 20 μ L and carries out
LC-MS/MS is analyzed；
The preparation of (1d) standard curve：The DTPA-Zn standard serial solutions of various concentrations are taken to add to blank human plasma respectively
In, it is configured to equivalent to the standard curve plasma sample that concentration is 1,2,5,10,20,50,100 and 200 μ g/mL；Take the blood plasma
The μ L of sample 50, sequentially add inner mark solution 10 μ L, the μ L of 0.1% ammoniacal liquor 50, water 400 μ L, vortex mixing 3min, are all splined on solid
Mutually on extraction pillar, then (1b) and (1c) is operated according to more than, and standard curve, the standard are drawn according to LC-MS/MS analysis results
Curve is used to calculate the target substance content in various samples；
(2) liquid chromatography tandom mass spectrometry determination：
(2a) provides high performance liquid chromatograph and tandem mass spectrometer, and the high performance liquid chromatograph is equipped with gradient pump and sample introduction
Device, the tandem mass spectrometer is equipped with electric spray ion source and data handling system；
(2b) chromatographic condition：(its specification is for example for the chromatographic columns of SHISEIDO Proteonavi brands for analytical column used
For 5 μm, 250 × 4.6mm I.D.), C is connected before post18(its specification is, for example, 4 × 3.0mm I.D., such as U.S. to guard column
The guard column of Phenomenex companies), 25 DEG C of column temperature, mobile phase is methanol -2mM ammonium formates (for example, wherein containing 0.03% ammonia
Water) (50:50, v/v), flow velocity 0.45mL/min；
(2c) Mass Spectrometry Conditions：Electro-spray ionization source (such as using Turbo Ionspray sources), negative-ion mode detection；
Injection electric is -4000V；Source temperature is 400 DEG C；Roller shutter gas (CUR) is 20；Collision gas (CAD) is 4；How anti-scan mode be
(MRM) should be monitored, the ionic reaction for quantitative analysis be respectively 226.6 → m/z of m/z 204.5 (Zn-DTPA, CE for-
15V) with 444.2 → m/z of m/z 319.2 (internal standard EDTA-Zn, CE are -34V), sweep time is 150msec；
(3) data process＆analysis
(3a) obtains the target substance content in biological sample by above-mentioned liquid chromatography tandom mass spectrometry determination；With optionally
's
(3b) with non-compartment model calculate selected from it is following once or multiple pharmacokinetic parameters：Cmax、Tmax、t1/2、MRT、
AUC0-t、Vz、CL；Wherein, CmaxFor the maximum plasma concentration of actual measurement, TmaxFor peak reaching time of blood concentration after oral administration, t1/2
Half-life period is eliminated for medication end, MRT is medicine mean residence time, lower area of blood concentration-time curve AUC in vivo0-t
Calculated and obtained by trapezoidal method, VzApparent volume of distribution during for stable state, CL is clearance rate；And, optional
(3c) calculates the bioavilability of administration：Waiting under the dosage, with AUC obtained by the second administering mode divided by
AUC is multiplied by with 100% gained percentage obtained by first administering mode, as the second administering mode relative to the first administering mode
Relative bioavailability.
Method described in any embodiment according to a first aspect of the present invention, wherein the rat plasma is from giving or not
The rat vein blood for giving Zn-DTPA is placed in the centrifuge tube containing liquaemin, and 2000~4000g centrifuges 10~30min (for example
3000g centrifuge 20min) obtain blood plasma.
Method described in any embodiment according to a first aspect of the present invention, the optional quilt of rat plasma obtained in it
Be placed in -20 DEG C of refrigerators and freeze, with etc. it is to be determined.
Method described in any embodiment according to a first aspect of the present invention, wherein the rat vein blood is from big rathole
The blood sampling of socket of the eye venous sinus is obtained.
Method described in any embodiment according to a first aspect of the present invention, wherein being designated as EDTA-Zn in used
Na2·xH2O。
Method described in any embodiment according to a first aspect of the present invention, wherein the solid phase extraction column is in loading
Before, first activated with 1mL methanol, then use 1mL water balances.
Method described in any embodiment according to a first aspect of the present invention, wherein the rat is, for example, Sprague-
Dawley (SD) rat, this area is often referred to simply as SD rats.
Method described in any embodiment according to a first aspect of the present invention, wherein the high performance liquid chromatograph is, for example,
The type liquid chromatographs of Agilent company of the U.S. Agilent 1200.
Method described in any embodiment according to a first aspect of the present invention, wherein the tandem mass spectrometer is, for example, the U.S.
The type tandem mass spectrometers of AB Sciex company API 4000；For example it is furnished with Turbo Ionspray ionization sources and Analyst
1.5 data handling system.
Method described in any embodiment according to a first aspect of the present invention, wherein described be used to pharmacokinetic parameters and calculate use
Software beSoftware, such as its version are 5.2.1 editions.
Method described in any embodiment according to a first aspect of the present invention, wherein in step (3a), the parameter of each group is equal
Represented with the mode that average data is " mean ± standard deviation "；Further, the average data is to be more than or equal to 3 with sample number
The average of gained.
Method described in any embodiment according to a first aspect of the present invention, wherein second administering mode is relative to
The relative bioavailability of one administering mode, is characterized, F (relative) % is counted by following calculating formula with F (relative) %：
In above formula：
AUC is TG-AUC (its unit is, for example, h* μ g/mL),
D is dosage (its unit is, for example, mg/kg).
Method described in any embodiment according to a first aspect of the present invention, when first administering mode is intravenous injection
When (i.e. Bolos intravenous administration) is administered, bioavilability of second administering mode for the Bolos intravenous administration mode is exhausted for its
To bioavilability, i.e., characterized with F (absolute) %, F (absolute) % is counted by following calculating formula：
For example, tracheae inhalation can use following formula relative to absolute bioavailability F (absolute) % of intravenous injection administration
Calculate：
In another example, under tracheae inhalation is available relative to relative bioavailability F (relative) % of intramuscular administration
Formula is calculated：
In the present invention, Proteonavi chromatographic columns are a kind of using in porous spherical silica filler surface bond butyl
(C4) high-performance protein-polypeptide analysis chromatographic column specially, the filler is both with the high separation capacity of silica type filler and resistance to
Pressure property, has the specialities such as acid resistance, the absorption for suppressing protein again.The chromatographic column is indicated with Proteonavi s5 sometimes.Although
The DTPA metal chelating agents that the present invention is analyzed are a kind of typical small-molecule substances, and molecular weight is much smaller than common protein-many
Peptide, however, having had now surprisingly been found that, the present invention is only under conditions of the chromatographic column using above-mentioned Proteonavi chromatographic columns
The inventive method could obtain excellent methodology performance.For example, using YMC-C18, Agilent Extard-C18, money life
During the C18 posts such as hall PAK CR-18 (it is same manufacturer with Proteonavi posts used herein), DTPA metal complexs are extremely
It is difficult to elute, such as using chromatographic condition of the present invention but DTPA-Za retention time is more than when using these C18 posts instead
43min and hangover is serious, however it is unaccountable be internal standard substance but not so serious extension retention time (different
Retention time is about between 5~6min on C18 posts).In another example, using ZORBAX EDIPSR-C8, Dikma diamonds-C8, taking
During the C8 posts such as sieve door Gemini-C8, DTPA metal complexs do not retain in the chromatography column, i.e., retention time is extremely short, for example
DTPA-Za retention time using chromatographic condition of the present invention but when using these C8 posts instead be less than 1.5min and with easy and solvent
It can not be efficiently separated etc. mixed in together.
Method described in any embodiment according to a first aspect of the present invention, wherein the solid phase extraction column is modelWAX solid phase extraction column, it is for example purchased from Waters companies.Waters Oasis WAX solid phase extraction columns are in business
Be typically in industry be configured as mixed type weak anionic exchange reverse phase absorption agent, have to highly acid compound high selectivity and
The solid phase extraction column of sensitivity.It has been had now surprisingly been found that, only ought use above-mentioned Oasis WAX type solid phase extraction columns
In the case of, the inventive method could obtain excellent methodology performance.And when the solid phase extraction column example for using other brands instead
Such as the U.S. Ai Jieer Cleanert PWAX solid phase extraction columns, StrataTM- X solid phase extraction columns and even same factory
During the Oasis MAX type solid phase extraction columns of business, it can not much obtain what above-mentioned Oasis WAX type solid phase extraction columns were obtained
Good results.For example when being tested according to the method involved by table 2 below result, with above-mentioned three kinds other brand/models
During solid phase extraction column, the μ g/mL of the rate of recovery 2,18 μ g/mL, 180 μ g/mL, tri- kinds of concentration rate of recovery respectively 36~41%, 45~
54%th, it is this in the range of 52~68% and various pillars gained RSD under three kinds of various concentrations is fluctuated in the range of 8~19%
Greatest differences are presented in the rate of recovery under various concentrations and the result of RSD wide fluctuations is unacceptable in biological sample analysis
's.In addition, when carrying out biological sample processing, after sample is loaded into solid phase extraction column, with the elution containing a small amount of ammoniacal liquor
It is necessary that liquid, which carries out elution, and otherwise the rate of recovery under each concentration is lower 20 hundred in table 2 below rate of recovery result of the present invention than it
It is more than branch.
In the step of aforesaid operations method of the present invention, although specific steps that it is described are in some details or language
The step of described in example in description with following detailed description part, is otherwise varied, however, those skilled in the art
Approach described above step can be summarized according to the detailed disclosure of full text of the present invention completely.
Any embodiment of the either side of the present invention, can be combined with other embodiments, as long as they are not
Contradiction occurs.In addition, in any embodiment of either side of the present invention, any technical characteristic goes for other realities
The technical characteristic in scheme is applied, as long as they are not in contradiction.The invention will be further described below.
All documents recited in the present invention, their full content is incorporated herein by reference, and if these are literary
Offer expressed implication with it is of the invention inconsistent when, be defined by the statement of the present invention.In addition, the various terms that use of the present invention and
Phrase has well known to a person skilled in the art general sense, nonetheless, the present invention remain desirable at this to these terms and
Phrase is described in more detail and explained that the term and phrase referred to is if any inconsistent with common art-recognized meanings, with institute's table of the present invention
The implication stated is defined.
The calcium metal chelating agent of DTPA metal chelating agents, such as DTPA or DTPA zinc metal chelating agent, their body
Outer detection, such as detection in some chemicals, preparation, are still that run into one of current those skilled in the art is huge
Problem is detected, and the detection difficulty in their vivo biodistribution samples is even more far more difficult than vitro detection.Particularly, current state
The inside and outside report all without analysis in these compound bodies.
DTPA calcium metal chelating agent, can be abbreviated as Ca-DTPA or DTPA-Ca, and it is generally also known as Ca-DTPA
(DTPA-CaNa3)；DTPA zinc metal chelating agent, can be abbreviated as Zn-DTPA or DTPA-Zn, and it is generally also known as Zn-
DTPA(DTPA-ZnNa3)。
The internal standard substance EDTA-Zn used in Ca-DTPA, Zn-DTPA and the present invention (is secondly sodium-salt hydrate
EDTA-Zn Na2xH2O) molecular formula be respectively with following formula A, formula B and formula C：
Wherein, Ca-DTPA can be injected intravenously and inhalation, be provided respectively with injection and powders for inhalation dosage form
In clinic, first batch of sample got the Green Light in 2004 in the U.S..The indications of Ca-DTPA clinically with application be：Ca-DTPA
As it is a kind of alleviate radiate chelating agent be used to make a definite diagnosis or it is doubtful by plutonium, americium, huge internal pollution subject treatment, and improve this
The clearance rate of a little metallic elements.
Ca-DTPA dosage gives the Ca-DTPA of first dosage with administration aspect, FDA code requirement in contaminated 24h
Treated, after 24h, it is proposed that maintain chelating therapy using Zn-DTPA.Used in 24h after chelating therapy is contaminated in vivo
Effect is best；Chelating therapy should be given in time when making a definite diagnosis or suspecting and be contaminated；If can not treat at once, permit in condition
Xu Shiying gives chelating therapy at once.A period of time chelating therapy after polluting in vivo is still effective.Radioactive pollutant exists
When during body-internal-circulation or in interstitial fluid, Ca chelate effect is optimal.Radioactivity after curative effect is chelated with internal pollution
Pollutant is isolated in liver and bone and reduced.If making a definite diagnosis or doubtful internal pollution not being caused by plutonium, americium, hard iron, need to carry out
Other treatment.Specific medication is that pollution channel is injected intravenously Ca- when not determining or there may exist multipath pollution
DTPA；5ml 3-4 minutes Ca-DTPA solution (1g/5ml) used time slow intravenous injection is administered, or 5ml Ca-DTPA is molten
Liquid is diluted to the administration of 100-250ml venous transfusions in 5% D/W, woods grignard lactic acid solution, physiological saline；If by
Examination person is contaminated due to suction, and the Ca-DTPA of atomization is given in 24h and can be used as therapy approach.
In addition, Zn-DTPA can be injected intravenously and inhalation, provided respectively with injection and powders for inhalation dosage form
In clinic, first batch of sample got the Green Light in 2004 in the U.S..The indications of Zn-DTPA clinically with application be：Zn-DTPA
Suitable for the internal pollution made a definite diagnosis or doubtful plutonium, americium, hard iron are caused, and accelerate its clearance rate.
Zn-DTPA dosage gives the Ca- of first dosage with administration aspect, FDA code requirement in contaminated 24h
DTPA is treated；Ca-DTPA is than Zn-DTPA better efficacy during this period；If Ca-DTPA is invalid, Zn-DTPA progress is given
Treat first.Given if second day extra chelation therapy of administration is proposed, conventional therapy is carried out using Zn-DTPA.If Zn-
DTPA is invalid, and chelating therapy is maintained using Ca-DTPA.Adjoint mineral supplements containing Zn should be given.To adult and green grass or young crops
Teenager, is injected intravenously the Zn-DTPA of 1g dosage；For the children of less than 12 years old, 14mg/Kg Zn-DTPA, consumption are injected intravenously
It is sure not more than 1g.Chelating continued treatment after 24h uses Zn-DTPA, to adult and teenager, intravenous injection 1g dosage
Zn-DTPA, once a day；For the children of less than 12 years old, 14mg/Kg Zn-DTPA is injected intravenously, once a day, consumption is not
More than 1g.Using effect is best in 24h after DTPA chelating therapy is contaminated in vivo.It is contaminated making a definite diagnosis or suspecting
When should give chelating therapy in time.If can not treat at once, chelating therapy should be given at once in conditions permit.It is dirty in vivo
A period of time chelating therapy after dye is still effective.Radioactive pollutant in vivo in cyclic process or in interstitial fluid when, Zn-
DTPA chelate effect is optimal.Radioactive pollutant is isolated in liver and bone and dropped after curative effect is chelated with internal pollution
It is low.If making a definite diagnosis or doubtful internal pollution not being caused by plutonium, americium, hard iron, other treatment need to be carried out.Specific medication is,
Pollution channel is injected intravenously Zn-DTPA when not determining or there may exist multipath pollution；By 5ml Zn-DTPA solution (1g/
5ml) slow intravenous injection administration in used time 3-4 minutes, or by 5ml Zn-DTPA solution in 5% D/W, woods grignard
The administration of 100-250ml venous transfusions is diluted in lactic acid solution, physiological saline；If subject merely due to inhalation route and get dirty
The Zn-DTPA of atomization is given in dye, 24h to be used as therapy approach.
By setting up the inventive method, the metallo-chelate for being DTPA is to give animal (such as rat, people) internal afterwards
The assay of these materials provides possible in biological sample (such as blood, urine, saliva).The analysis that the present invention is set up
Method has excellent methodology performance.
Brief description of the drawings
Fig. 1：In DTPA-Zn and EDTA-Zn second order mses figure, figure, A is DTPA-Zn, and B is EDTA-Zn (internal standard).
Fig. 2：In the MRM chromatograms of rat plasma sample, figure, A is blank plasma, B for plus internal standard blank plasma, C be to
Medicine plasma sample；In addition, in figure, peak I is DTPA-Zn, peak II is internal standard EDTA-Zn.
Fig. 3：DTPA-Zn samples determine a standard curve (y=0.0706x+0.0309) in stage.
Embodiment
Following examples provided by the present invention are only used for task of explanation rather than are used for, and are also not necessarily to be construed as with any
Mode limits the present invention.Those skilled in the art will recognize that in the case of not past the spirit or scope of the present invention
Following examples can be made with conventional change and modifications.
It is an object of the present invention to more fully understand DTPA-Zn disposition rule, present invention experiment is set up simultaneously
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method of DTPA-Zn content in quantitative detection biological sample is demonstrated, is investigated simultaneously
Pharmacokinetics and bioavilability situation of the DTPA-Zn in rat body.
First, experiment material
1st, medicine, reagent and material
Zn-DTPA(DTPA-ZnNa3) raw material, white powder, content 84.95%, self-control.
Zn-DTPA powder sprays, white powder, content：53.45%, self-control.
Zn-DTPA parenteral solutions, self-control.
Ethylenediamine tetraacetic acid disodium zinc salt salt hydrate (internal standard, EDTA-Zn Na2·xH2O), white crystalline powder, purity
＞ 98.0%, purchased from uncommon love (Shanghai) the chemical conversion industry Development Co., Ltd of ladder.
Methanol (chromatographically pure) is U.S.'s Fisher Products；Formic acid (analysis is pure), ammonium formate (analysis is pure) are purchased from state
Chemical reagent Co., Ltd of medicine group；Water is Wahaha deionized water.
Solid phase extraction column is purchased from Waters companies, modelWAX, 1cc.
2nd, instrument
Liquid chromatograph-mass spectrometer (LC-MS/MS)：The type tandem mass spectrometers of American AB Sciex company API 4000 (are matched somebody with somebody
There are Turbo Ionspray ionization sources and the data handling systems of Analyst 1.5)；Agilent company of the U.S. Agilent
1200 quaternary gradient pumps and automatic sampler.
BA11OS type a ten thousandths electronic analytical balance (German Sartorius companies)；QB-600 types vortex mixer (sea
Its woods Bel's instrument manufacturing Co., Ltd of retail sales produces)；(the sensible scientific and technological Limited Liability in Beijing is public for TDW-1 type heated at constant temperature instrument
Department)；WYK-45D types air compressor (Tianjin dyne instrument plant).
3rd, experimental animal
Sprague-Dawley (SD) rat, male, body weight is 260 ± 20g, and credit number is SCXK (capital) 2012-
0001, quality certification number：11400700051827, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..
2nd, experimental method
1st, LC-MS/MS conditions
Chromatographic condition：Analytical column is SHISEIDO Proteonavi (5 μm, 250 × 4.6mm I.D., Japanese SHISEIDO
Company), connect C18Guard column (4 × 3.0mm I.D., Phenomenex companies of the U.S.), 25 DEG C of column temperature, mobile phase be methanol-
2mM ammonium formates (containing 0.03% ammoniacal liquor) (50:50, v/v), flow velocity 0.45mL/min, is inside designated as EDTA-Zn Na2·xH2O。
Mass Spectrometry Conditions：Electro-spray ionization source (Turbo Ionspray sources), negative-ion mode detection；Injection electric for-
4000V；Source temperature is 400 DEG C；Roller shutter gas (CUR) is 20；Collision gas (CAD) is 4；Scan mode is multiple-reaction monitoring (MRM),
Ionic reaction for quantitative analysis is respectively 226.6 → m/z of m/z 204.5 (Zn-DTPA, CE are -15V) and m/z 444.2
→ m/z 319.2 (internal standard EDTA-Zn, CE are -34V), sweep time is 150msec.
2nd, biological sample is handled
Take the μ L of blood plasma 50, plus μ L, 50 μ L 0.1% ammoniacal liquor of inner mark solution (the 25 μ g/mL EDTA-Zn aqueous solution) 10,400 μ L
Water, vortex mixing 3min, is all splined on solid phase extraction column.First activated before solid phase extraction column loading with 1mL methanol, then
Use 1mL water balances.Cleaned successively with 1mL water, 1mL methanol after loading, finally with 1mL methanol (containing 5% ammoniacal liquor) elution.Collection is washed
De- liquid drying, is redissolved with the methanol of 150 μ L 50% (containing 0.05% ammoniacal liquor), draws 20 μ L and carry out LC-MS/MS analyses, determine and count
Calculate the content of the target substance in biological sample.
3rd, Zn-DTPA rat experiment method
Male SD rat 18, is randomly divided into 3 groups, every group 6, Zn-DTPA parenteral solutions, flesh are given in respectively intravenous injection
Zn-DTPA parenteral solutions are given in meat injection and tracheae sprays into Zn-DTPA powder spray groups, and dosage is Zn-DTPA50mg/kg (with Zn-
DTPA is calculated).Animal administration before non-fasting, free water, respectively at administration before and administration after 0.03,0.08,0.17,0.25,
0.5th, 0.75,1,2,4 and 6h orbital sinus blood sampling 0.2mL, is placed in the centrifuge tube containing liquaemin, 3000g centrifugation 20min,
Take blood plasma be placed in -20 DEG C of refrigerators freeze it is to be measured.
4th, data process＆analysis
Pharmacokinetic parameters are usedThe non-compartment model of software (Version 5.2.1, the U.S.) is calculated.CmaxFor reality
The maximum plasma concentration of survey, TmaxFor peak reaching time of blood concentration after oral administration, t1/2Half-life period, MRT are eliminated for medication end
For medicine mean residence time, lower area of blood concentration-time curve AUC in vivo0-tCalculated and obtained by trapezoidal method, VzTo be steady
Apparent volume of distribution during state, CL is clearance rate.Class mean is according to " mean ± standard deviation ", (Mean ± SD, n >=3) are represented.
The calculating of bioavilability：Sucked by tracheae and the AUC ratio calculations of intravenous (or intramuscular injection) obtain corresponding dosage Zn-
Absolute (or relative) bioavilability of DTPA powder sprays, calculation formula is as follows：
In formula, AUC：TG-AUC (h* μ g/mL)；D：Dosage (mg/kg)
3rd, result and evaluation
1st, LC-MS/MS quantitation methodologies and checking
(1) selectivity of method
Plasma sample after blank plasma, mark-on blank plasma and rat are administered, as described above operation carries out LC-
MS/MS is analyzed, and obtains MRM chromatograms.More visible through chromatogram, the endogenous material in rat plasma does not disturb determinand
And interior target is determined.Two grades of full scan mass spectrograms of determinand are shown in Fig. 1, and the MRM chromatograms of rat plasma sample are shown in Fig. 2.Zn-
DTPA and interior target chromatographic retention (tR) it is respectively 4.9min and 5.3min (Fig. 2).
(2) standard curve and lower limit of quantitation
Take the DTPA-Ca standard serial solutions of various concentrations to add to respectively in blank rat plasma, be configured to equivalent to dense
Spend for 1,2,5,10,20,50,100 and 200 μ g/mL standard curve plasma sample；The plasma sample 50 μ L are taken, are sequentially added
Inner mark solution 10 μ L, the μ L of 0.1% ammoniacal liquor 50, water 400 μ L, vortex mixing 3min, are all splined on solid phase extraction column, then
Cleaned, finally eluted with the methanol 1mL containing 5% ammoniacal liquor with 1mL water, 1mL methanol successively after loading；The eluent is collected, is dried up,
Redissolved with the μ L of 50% methanol 150 containing 0.05% ammoniacal liquor, draw 20 μ L and carry out LC-MS/MS analyses；Analyzed and tied according to LC-MS/MS
Fruit draws standard curve, and the standard curve is used to calculate the target substance content in various samples；
Using testing concentration as abscissa, the peak area ratio of determinand and internal standard compound is ordinate, with weighting (W=1/
X2) least square method progress regressing calculation, Zn-DTPA linear regression equation is tried to achieve, standard curve is shown in Fig. 3.Zn-DTPA is 1
It is in good linear relationship (r in the range of~200 μ g/mL, between concentration and peak area ratio2>0.998).By 6 sample analyses
Preci-sion and accuracy, determine lower limit of quantitation be 1 μ g/mL.
(3) precision of method and the degree of accuracy
Add the QC of internal standard preparation low, medium and high three concentration of Zn-DTPA (2,18 and 180 μ g/mL) with rat blank plasma
Sample, carried out 6 sample analyses to each concentration in one day, obtains the withinday precision and the degree of accuracy of this law, be carried out continuously 6 samples
This analysis, obtains day to day precision and the degree of accuracy.The result of table 1 shows that the preci-sion and accuracy of method meets biological sample
Product quantitative analysis requirement.
Table 1：Zn-DTPA precision and the degree of accuracy (n=18)
(4) rate of recovery and matrix effect
The rat plasma QC samples of 3 concentration are prepared, each concentration carries out 3 sample analyses, and the standard with same concentrations is molten
Liquid sample carries out peak area ratio and is relatively recycled rate, and data are shown in Table 2.The result from table, time of low, medium and high three concentration
Yield is basically identical.
Table 2：The Zn-DTPA blood plasma rate of recovery (n=3)
In 3 QC concentration levels, the method for mark-on (that is, plus internal standard substance), has investigated Zn- after being extracted using blank plasma
Matrix effects of the DTPA in rat plasma sample, the results are shown in Table 3.Test result indicates that in rat plasma Zn-DTPA matrix
Effect is between 85%~115%, measure no significant impact of the plasma matrix to Zn-DTPA.
Table 3：Zn-DTPA matrix effect (n=5)
| QC concentration (μ g/mL) | Matrix effect (%) | Relative standard deviation (RSD%) | Relative deviation (RE%) |
| 2 | 99.7±5.3 | 5.3 | -0.3 |
| 18 | 92.4±6.8 | 7.4 | -7.6 |
| 180 | 105.5±5.3 | 5.1 | 5.5 |
(5) study on the stability
In 3 QC concentration levels, stability of the Zn-DTPA plasma samples under various experiment conditions has been investigated.As a result table
Bright, Zn-DTPA RSD is respectively less than 9.9%, RE (table 4) in the range of -8.25~9.87%, and the stability of the two meets this
Test requirements document.
Table 4：DTPA-Zn stability (n=4) in plasma sample
2nd, DTPA-Zn pharmacokinetics in rats
The present invention is given after 50mg/kgZn-DTPA using male rat intravenous injection, intramuscular injection and tracheae suction, is examined
Their plasma pharmacokinetics are examined, in different sampling time points, active compound averaged plasma drug in three kinds of administering modes are determined dense
Spend (these data are not provided specifically in this application), according to these averaged plasma drug concentration datas can draw average medicine-
When curve.
Surveyed data are analyzed with Winnonlin pharmacokinetic programs, main pharmacokinetic parameter is obtained,
As a result show, intravenous injection, intramuscular injection and tracheae suck the t of three kinds of modes1/2Respectively in the range of 0.3~0.4h, 0.4~
In the range of 0.6h and in the range of 0.7~0.9h, the C of three kinds of modesmaxRespectively in the range of 200~300 μ g/mL, 90~140 μ
In the range of g/mL and in the range of 60~80 μ g/mL, the AUC of three kinds of modes(0-t)Respectively in the range of 80~95h* μ g/mL, 85~
In the range of 95h* μ g/mL and in the range of 45~55h* μ g/mL.In addition, being computed, rat transtracheal suction Zn-DTPA powder sprays
Body absorption and elimination after (50mg/kg) is very fast, and the peak time of active compound is 3min, t1/2For 0.81 ± 0.17h, in vivo
Average residence time MRT is 0.91 ± 0.24h, and 2.0h blood concentrations are down to less than the 1/10 of Cmax, Absolute oral after administration
Availability F is 55.32%, and compared with intramuscular injection, relative bioavailability is 53.37%.These results show liquid of the present invention
Phase chromatogram-tandem mass spectrometry is feasible for determining the DTPA metal complexs in biological sample.
Generally speaking, the present invention sets up and demonstrates the LC-MS/MS methods of Zn-DTPA in quantitative detection biological sample, side
Specificity, reappearance and the accuracy of method meet the requirement of pharmacokinetic.Rat intravenous injection 50mg/kg Zn-
After DTPA parenteral solutions, active compound is eliminated quickly in blood plasma, t1/2For 0.38h, after administration 4.0h plasma concentration be down to test limit with
Under.After rat muscle injection Zn-DTPA parenteral solutions, the absorption of active compound and also very fast, the T of eliminationmaxIn 8min or so, t1/2For
0.5h, average residence time MRT are 0.6h or so, and bioavilability is 103.6%.Rat trachea sucks Zn-DTPA powder sprays
Afterwards, active compound absorbs and eliminated very fast, TmaxIn 3min or so, t1/2For 0.8h, average residence time MRT is 0.9h, definitely raw
Thing availability is 55.32%, and compared with intramuscular injection, relative bioavailability is 53.37%.
Reference：State food and Drug Administration：《Chemicals Non-clinical Pharmacokinetics investigative technique refers to
Lead principle》, 2005.3.
The spirit of the present invention is elaborated above by present pre-ferred embodiments.Those skilled in the art manage
Solution, every any modification, equivalent variations and modification substantially made according to the technology of the present invention to above example, all falls within this hair
In bright protection domain.
Claims (10)
1. determining the method for the DTPA-Zn in rat plasma biological sample, this method uses LC-MS/MS
The content of DTPA-Zn in rat plasma biological sample through processing, comprises the following steps：
(1) processing of biological sample：
(1a) takes the μ L of rat plasma 50 for containing or not contain DTPA-Zn, is placed in 1.5mL centrifuge tubes, plus inner mark solution is 25 μ
The g/mL μ L of the EDTA-Zn aqueous solution 10 are not added with inner mark solution, the μ L of 0.1% ammoniacal liquor 50, water 400 μ L, vortex mixing 3min, entirely
Portion is splined on solid phase extraction column；
Cleaned, finally eluted with the methanol 1mL containing 5% ammoniacal liquor with 1mL water, 1mL methanol successively after (1b) loading；
(1c) collects the eluent, drying, is redissolved with the μ L of 50% methanol 150 containing 0.05% ammoniacal liquor, draws 20 μ L and carries out LC-
MS/MS is analyzed；
The preparation of (1d) standard curve：Take the DTPA-Zn standard serial solutions of various concentrations to add to respectively in blank human plasma, match somebody with somebody
It is made equivalent to the standard curve plasma sample that concentration is 1,2,5,10,20,50,100 and 200 μ g/mL；Take the plasma sample
50 μ L, sequentially add inner mark solution 10 μ L, the μ L of 0.1% ammoniacal liquor 50, water 400 μ L, vortex mixing 3min, are all splined on solid phase extraction
Take on pillar, then (1b) and (1c) is operated according to more than, standard curve, the standard curve are drawn according to LC-MS/MS analysis results
For calculating the target substance content in various samples；
(2) liquid chromatography tandom mass spectrometry determination：
(2a) provides high performance liquid chromatograph and tandem mass spectrometer, and the high performance liquid chromatograph is equipped with gradient pump and injector,
The tandem mass spectrometer is equipped with electric spray ion source and data handling system；
(2b) chromatographic condition：(its specification is, for example, 5 μ to analytical column used for the chromatographic columns of SHISEIDO Proteonavi brands
M, 250 × 4.6mm I.D.), C is connected before post18(its specification is, for example, 4 × 3.0mm I.D., such as U.S. to guard column
The guard column of Phenomenex companies), 25 DEG C of column temperature, mobile phase is methanol -2mM ammonium formates (for example, wherein containing 0.03% ammonia
Water) (50:50, v/v), flow velocity 0.45mL/min；
(2c) Mass Spectrometry Conditions：Electro-spray ionization source (such as using Turbo Ionspray sources), negative-ion mode detection；Injection
Voltage is -4000V；Source temperature is 400 DEG C；Roller shutter gas (CUR) is 20；Collision gas (CAD) is 4；Scan mode is many reaction prisons
Survey (MRM), the ionic reaction for quantitative analysis be respectively 226.6 → m/z of m/z 204.5 (Zn-DTPA, CE are -15V) and
444.2 → m/z of m/z 319.2 (internal standard EDTA-Zn, CE are -34V), sweep time is 150msec；
(3) data process＆analysis
(3a) obtains the target substance content in biological sample by above-mentioned liquid chromatography tandom mass spectrometry determination；With, optional
(3b) with non-compartment model calculate selected from it is following once or multiple pharmacokinetic parameters：Cmax、Tmax、t1/2、MRT、AUC0-t、
Vz、CL；Wherein, CmaxFor the maximum plasma concentration of actual measurement, TmaxFor peak reaching time of blood concentration after oral administration, t1/2For medicine
Terminal elimination half-life, MRT is medicine mean residence time, lower area of blood concentration-time curve AUC in vivo0-tBy trapezoidal
Method is calculated and obtained, VzApparent volume of distribution during for stable state, CL is clearance rate；And, optional
(3c) calculates the bioavilability of administration：Waiting when under dosage, with AUC divided by first obtained by the second administering mode
AUC obtained by administering mode is multiplied by with 100% gained percentage, the phase as the second administering mode relative to the first administering mode
To bioavilability.
2. method according to claim 1, wherein the rat plasma is from the rat vein blood for giving or not giving Zn-DTPA
It is placed in the centrifuge tube containing liquaemin, 2000~4000g centrifuges the blood that 10~30min (such as 3000g centrifuges 20min) is obtained
Slurry.
3. method according to claim 1, rat plasma obtained in it being placed in -20 DEG C of refrigerators optionally freezes, with
Etc. to be determined.
4. method according to claim 1, wherein the rat vein blood is obtained from the blood sampling of rat orbital sinus.
5. method according to claim 1, wherein being designated as EDTA-Zn Na in used2·xH2O。
6. method according to claim 1, wherein the solid phase extraction column is before loading, is first activated, then use with 1mL methanol
1mL water balances.
7. method according to claim 1, wherein the rat is, for example, Sprague-Dawley (SD) rat, this area is usual
Referred to as SD rats.
8. method according to claim 1, wherein：
The high performance liquid chromatograph is, for example, the type liquid chromatographs of Agilent company of the U.S. Agilent 1200；
The tandem mass spectrometer is, for example, the type tandem mass spectrometers of American AB Sciex company API 4000；For example it is furnished with Turbo
Ionspray ionization sources and the data handling systems of Analyst 1.5；
The software for pharmacokinetic parameters calculating isSoftware, such as its version are 5.2.1 editions.
9. method according to claim 1, wherein Relative biological profit of second administering mode relative to the first administering mode
Expenditure, is characterized, F (relative) % is counted by following calculating formula with F (relative) %：
In above formula：
AUC is TG-AUC (its unit is, for example, h* μ g/mL),
D is dosage (its unit is, for example, mg/kg).
10. method according to claim 1, wherein the solid phase extraction column is modelWAX SPE is small
Post.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710553621.6A CN107167541B (en) | 2017-07-08 | 2017-07-08 | The method for measuring the DTPA-Zn in rat plasma biological sample |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710553621.6A CN107167541B (en) | 2017-07-08 | 2017-07-08 | The method for measuring the DTPA-Zn in rat plasma biological sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107167541A true CN107167541A (en) | 2017-09-15 |
| CN107167541B CN107167541B (en) | 2019-08-02 |
Family
ID=59823439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710553621.6A Active CN107167541B (en) | 2017-07-08 | 2017-07-08 | The method for measuring the DTPA-Zn in rat plasma biological sample |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107167541B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109030668A (en) * | 2018-10-24 | 2018-12-18 | 上海司太立制药有限公司 | The high efficient liquid phase analysis method of Primovist intermediate |
| WO2022206806A1 (en) | 2021-03-31 | 2022-10-06 | 荣昌生物制药(烟台)股份有限公司 | Method for measuring content of dtpa in adc by means of using lc-ms/ms |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831166B2 (en) * | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| CN101573384A (en) * | 2006-10-27 | 2009-11-04 | 健泰科生物技术公司 | Antibodies and immunoconjugates and uses therefor |
-
2017
- 2017-07-08 CN CN201710553621.6A patent/CN107167541B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831166B2 (en) * | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| CN101573384A (en) * | 2006-10-27 | 2009-11-04 | 健泰科生物技术公司 | Antibodies and immunoconjugates and uses therefor |
Non-Patent Citations (5)
| Title |
|---|
| ANDREA SCOZZAFAVA等: "carbonic anhydrase inhibitors:synthesis of sulfonamides incorporating dtpa tails and of their zinc comp;exes with powerful topical antiglaucoma properties", 《BIOORGANIC ＆ MEDICINAL CHEMISTRY LETTERS》 * |
| MIKA SILLANPAA等: "Analysis of EDTA and DTPA", 《TALANTA》 * |
| WOLFGANG BUCHBERGER等: "Determination of Chelating Agents and Metal Chelates by Capillary Zone Electrophoresis", 《MIKROCHIM. ACTA》 * |
| ZULIANG CHEN等: "Speciation of Zn-aminopolycarboxylic complexes by electrospray ionization mass spectrometry and ion chromatography with inductively coupled plasma mass spectrometry", 《RAPID COMMUN. MASS SPECTROM.》 * |
| 陈红红等: "反相高效液相色谱法测定二乙烯三胺五醋酸注射液的含量", 《中国现代应用药学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109030668A (en) * | 2018-10-24 | 2018-12-18 | 上海司太立制药有限公司 | The high efficient liquid phase analysis method of Primovist intermediate |
| CN109030668B (en) * | 2018-10-24 | 2021-03-09 | 上海司太立制药有限公司 | High performance liquid phase analysis method of gadoxetic acid disodium intermediate |
| WO2022206806A1 (en) | 2021-03-31 | 2022-10-06 | 荣昌生物制药(烟台)股份有限公司 | Method for measuring content of dtpa in adc by means of using lc-ms/ms |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107167541B (en) | 2019-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yi et al. | Study of the accumulation and distribution of arsenic species and association with arsenic toxicity in rats after 30 days of oral realgar administration | |
| US9737260B2 (en) | Methods for determining total body skeletal muscle mass | |
| CN107315056B (en) | The method for measuring the DTPA-Ca in rat plasma biological sample | |
| Palumbo et al. | Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2, 5-dihydroxybenzoic acid in endoscopie intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection | |
| CN102353732B (en) | Quality detection method of Zhenlong brain-refreshment preparation | |
| Myers et al. | High-performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum | |
| Sagirli et al. | Determination of gabapentin in human plasma and urine by high-performance liquid chromatography with UV–vis detection | |
| CN107167541B (en) | The method for measuring the DTPA-Zn in rat plasma biological sample | |
| CN111781290A (en) | Kit and detection method for accurately determining blood concentration of multiple antiepileptic drugs in human serum | |
| CN107340343B (en) | The method for measuring the DTPA-Zn in human plasma biological sample | |
| CN107167540B (en) | The method for measuring the DTPA-Zn in human urine biological sample | |
| Zhang et al. | Determination of 25-OH-PPD in rat plasma by high-performance liquid chromatography–mass spectrometry and its application in rat pharmacokinetic studies | |
| CN107014915A (en) | The quantitative detecting method of abiraterone in whole blood | |
| Bahgat et al. | HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application | |
| CN110702888A (en) | Liver and kidney clearance detection method for two isomers of Pumei | |
| Wang et al. | Measurement of 1-and 3-methylhistidine in human urine by ultra performance liquid chromatography–tandem mass spectrometry | |
| Seregina et al. | Matrix interference in the determination of elements in biological samples by inductively coupled plasma–mass spectrometry and methods for its elimination | |
| Sabatier et al. | Comparison of stable-isotope-tracer methods for the determination of magnesium absorption in humans | |
| CN104833756B (en) | A kind of content assaying method of attached sweet medicine monoester alkaloid | |
| CN108663442B (en) | Method for checking related substances of alfacalcidol tablet | |
| Wang et al. | Population pharmacokinetics of naringin in total flavonoids of Drynaria fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis | |
| Danh et al. | Development and validation of a liquid chromatography-mass spectrometry method for the simultaneous quantification of artesunate and dihydroartemisinin in human plasma | |
| CN113820404B (en) | UPLC analysis method of ipratropium bromide aerosol | |
| Borges et al. | Comparative bioavailability study with two gemfibrozil tablet formulations in healthy volunteers | |
| Foteeva et al. | Application of capillary electrophoresis to the analysis of metal-containing pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |